Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of Cohort 6 of the COSMIC-021 Study.
Publication/Presentation Date
2-2020
Volume
38
Issue
6
Published In/Presented At
DOI: 10.1200/JCO.2020.38.6_suppl.13
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
Department(s)
Administration and Leadership
Document Type
Article
COinS